



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TICKLE, et al.

Atty. Ref.: 620-282

Serial No. 10/690,991

Group: unknown

Filed: October 23, 2003

Examiner: unknown

For: CRYSTAL STRUCTURE OF CYTOCHROME P450

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 23, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. Also attached is the International Search Report issued in connection with PCT/GB02/02668.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☒ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement

TICKLE et al..
Serial No. 10/690,991


was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B.J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Applicant

(Use several sheets if necessary)

TICKLE, et al.

Filing Date

Gr up

October 23, 2003

[illegible][illegible]

	Williams et al., "Mammalian Microsomal Cytochrome P450 Monooxygenase: Structural Adaptations for Membrane Binding and Functional Diversity," Molecular Cell, Vol. 5 (January 2000), pp. 121-131
	Wachenfeldt et al., "Microsomal P450 2C3 Is Expressed as a Soluble Dimer in Escherichia coli Following Modifications of Its N-terminus," Archives of Biochemistry and Biophysics, Vol. 339, No. 1 (March 1997), pp. 107-114
	Cosme et al., "Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme," The Journal of Biological Chemistry, Vol. 275, No. 4 (January 2000), pp. 2545-2553
	Hasemann et al., "Crystal Structure and Refinement of Cytochrome P450 _{terp} at 2.3 Å Resolution," J. Mol. Biol. 236 (1994), pp. 1169-1185
	Lewis, David, "Homology modeling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity," Exp Toxic Pathol. 51 (1999), pp/ 369-374
	Ibeanu et al., "Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity," The Journal of Biological Chemistry, Vol. 271, No. 21 (May 1988), pp. 12496-12501

Date Considered

802656